47 Hulfish Street
Princeton, NJ 08542
United States
609 662 2000
https://amicusrx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 517
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Bradley L. Campbell M.B.A. | CEO, President & Director | 984.09k | 461.21k | 1976 |
Ms. Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary | 733.94k | N/A | 1963 |
Mr. David M. Clark | Chief People Officer | 701.39k | N/A | 1975 |
Dr. Jeffrey P. Castelli | Chief Development Officer | 709.64k | 88.61k | 1972 |
Mr. Simon Nicolas Reade Harford | Chief Financial Officer | N/A | N/A | 1960 |
Ms. Samantha Prout | Chief Accounting Officer & Controller | N/A | N/A | 1978 |
Dr. Jill Weimer Ph.D. | Chief Science Officer | N/A | N/A | N/A |
Andrew Faughnan | Senior Director of Investor Relations | N/A | N/A | N/A |
Mr. Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer | N/A | N/A | N/A |
Ms. Diana Moore | Head of Global Corporate Communications | N/A | N/A | N/A |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 7; Compensation: 5.